FiercePharma1h
With new patient resource to close conversation gaps in rheumatic disease, AbbVie makes 'Rheum for Dialogue'
Many patients with rheumatic diseases refrain from telling their doctors about all physical and emotional symptoms they’re ...
pharmaphorum3h
AbbVie bags EU nod for key drug from ImmunoGen takeover
AbbVie's $10.1 billion takeover of ImmunoGen has been rewarded with EU approval for Elahere, the first drug specifically ...
AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer and full approval earlier this year, was the key asset in AbbVie's $10.1 billion ...
pharmaphorum6h
Syndax gets FDA okay for first-in-class leukaemia drug
Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light ...
BioSpace10h
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 14th of February ...